Claseprubart

克雷扑拜单抗

Report date: 2026/03/28 20:00:32

Base Information

Drug NameClaseprubart
Drug Alias NameDNTH-103DNTH103
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-Complement C1s
TargetsComplement C1s
Therapy Area/IndicationsMultifocal Motor NeuropathyAutoimmune DiseasesMotor Neuron Disease +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDianthus Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTenacia Biotechnology (Shanghai) Co LtdDianthus Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultifocal Motor NeuropathyAutoimmune DiseasesMotor Neuron Disease +[6] 
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A